Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis C virus].

M Roggendorf1, U Schlipköter

  • 1Max von Pettenkofer-Institut, Universität München.

Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) RNA is detectable early, but antibodies appear later. Current tests diagnose chronic HCV well but struggle with acute or past infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection.

Journal of viral hepatitis·2015
Same author

Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors.

Bone marrow transplantation·2015
Same author

Performance characteristics of the VERSANT hepatitis C virus RNA 1.0 (kPCR) assay.

International journal of medical microbiology : IJMM·2015
Same author

Adhesive luting of new CAD/CAM materials.

International journal of computerized dentistry·2015
Same author

[Combined hepatitis A/B vaccination: evaluation of a vaccination schedule in facilities for handicapped people].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2013
Same author

Hepatitis B virus carrier rate, prevalence and susceptibility and impact of immunization program among households in the city of Taiz, Yemen.

Vaccine·2012
Same journal

[Not Available].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Preliminary results of the 2nd multicenter study. Thrombocytapheresis with the Fresenius AS-104 blood cell separator and ring study of cell counting. Section of Therapeutic and Preparative Hemapheresis of the DGTI].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Thrombocyte substitution in hematologic patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Substitution of thrombocyte concentrates in polytransfused patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for fresh frozen plasma: evaluation of virus inactivating preparations].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for irradiated blood components: dose and side effects].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
See all related articles

Area of Science:

  • Virology
  • Immunology
  • Diagnostic Medicine

Context:

  • Hepatitis C virus (HCV) is a significant global health concern.
  • Understanding HCV infection dynamics is crucial for effective diagnosis and management.
  • High-risk populations like hemophiliacs, i.v. drug users, and hemodialysis patients exhibit elevated HCV prevalence.

Purpose:

  • To evaluate the diagnostic utility of current serological tests for Hepatitis C virus (HCV) infection.
  • To differentiate between acute, chronic, and past HCV infections based on viral RNA and antibody detection.
  • To assess the performance of second-generation ELISA in detecting antibodies to structural and nonstructural HCV proteins.

Summary:

  • Hepatitis C virus (HCV) RNA is detectable in serum as early as three days post-infection.

Related Experiment Videos

  • Antibodies against HCV are typically detected 3-4 months after infection.
  • Second-generation ELISA detects antibodies to both structural (core/C22) and nonstructural (C100, 3c) HCV proteins.
  • While patients with chronic HCV maintain long-term antibody persistence (anti-C100), recovered patients may lose antibodies within 2-3 years.
  • Current diagnostic tools are effective for chronic HCV but limited for diagnosing acute or past infections.

    • Impact:

    • Highlights limitations of current serological tests in diagnosing acute and past HCV infections.
    • Emphasizes the need for improved diagnostic strategies for early and resolved HCV cases.
    • Informs clinical practice regarding the interpretation of HCV test results in different patient groups and infection stages.